These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36111795)

  • 1. Recent advances in dopamine D
    Juza R; Musilek K; Mezeiova E; Soukup O; Korabecny J
    Med Res Rev; 2023 Jan; 43(1):55-211. PubMed ID: 36111795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers.
    Soriano A; Ventura R; Molero A; Hoen R; Casadó V; Cortés A; Fanelli F; Albericio F; Lluís C; Franco R; Royo M
    J Med Chem; 2009 Sep; 52(18):5590-602. PubMed ID: 19711895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
    Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
    J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, Biological, and Computational Evaluation of Substituted 1-(2-Methoxyphenyl)-4-(1-phenethylpiperidin-4-yl)piperazines and 1-(2-Methoxyphenyl)-4-[(1-phenethylpiperidin-4-yl)methyl]piperazines as Dopaminergic Ligands.
    Penjišević JZ; Šukalović VV; Andrić DB; Roglić GM; Šoškić V; Kostić-Rajačić SV
    Arch Pharm (Weinheim); 2016 Aug; 349(8):614-26. PubMed ID: 27335270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Lipids in Allosteric Modulation of Dopamine D
    Żuk J; Bartuzi D; Miszta P; Kaczor AA
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric Modulators of Dopamine D
    Kaczor AA; Wróbel TM; Bartuzi D
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
    Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
    Jutkiewicz EM; Bergman J
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discriminative stimulus effects of the neurotensin NTS1 receptor agonist PD149163 in rats: stimulus generalization testing with dopamine D1 and D2 receptor ligands.
    Prus AJ; Schuck CJ; Rusch KR; Carey LM
    Drug Dev Res; 2014 Mar; 75(2):47-58. PubMed ID: 24668440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D3 receptor ligands with antagonist properties.
    Hackling AE; Stark H
    Chembiochem; 2002 Oct; 3(10):946-61. PubMed ID: 12362359
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.